Early last summer, Walmart announced the launch of a new private brand, cash-pay analog insulin, made by drug manufacturer Novo Nordisk. Sold under Walmart’s private ReliOn label, vials go for $72.88 each and FlexPens for $85.88 each. Walmart calculates that the products will save customers between 58% and 75% of the cash price for branded analog insulin products, which translates to savings of up to $101 per branded vial or $251 per package of branded FlexPens. But, for many who struggle with the day-to-day costs of living with diabetes, these brands may still be tough to afford. Other pharmacies or drug-maker patient assistance programs may offer more support to cash-strapped patients.

Researchers of a new study published in BMJ say that extended-release metformin could prolong gestation in women with preterm preeclampsia.

Health care providers often hear that patients want to receive care from someone who looks like them. In the medical sphere, a growing body of research even supports the claim that this leads to better care, but the majority of physicians are not representative of certain minority groups.

September 9, 2021, was a busy day for the federal government and pharmacy stakeholders alike: Just a few hours apart, we saw significant developments in pharmacists’ COVID-19 pandemic practice authorities and prescription drug pricing. Both items yielded positive news for pharmacists and their patients.

In a recent conversation with a patient’s wife, Justin Ruffridge, PharmD, learned a lot more about the patient’s condition than he expected.